MAPT and Alzheimer disease: A key outcome has been the identification of several development candidates pursuing the relevance of the aggregated protein theory in neurodegenerative diseases by reducing brain accumulation of β-amyloid or phosphorylated tau in Alzheimer's disease[4] or α-synuclein in Parkinson's disease[5].